New Weight Loss Peptides in 2026: The Complete Pipeline Roundup

Key takeaways:

• At least 6 major weight loss compounds are in late-stage clinical trials as of early 2026
• Retatrutide (Eli Lilly) leads on raw efficacy with 24.2% weight loss in Phase 2, now in Phase 3
• Orforglipron (Eli Lilly) could be the first effective oral non-peptide GLP-1 -- no injections required
• Survodutide (Boehringer Ingelheim) shows particular promise for liver fat and MASH
• CagriSema (Novo Nordisk) combines semaglutide with an amylin analog for enhanced results
• The pipeline is shifting from single-receptor to multi-receptor approaches as the new standard

Important: This article is for educational and informational purposes only. It is not medical advice. All compounds discussed in the pipeline section are investigational and NOT FDA-approved for weight management unless otherwise noted. Always consult a qualified healthcare provider before making health decisions. See our full medical disclaimer.

The weight loss pipeline has never been this full

Two years ago, the conversation was simple: semaglutide or tirzepatide. In 2026, the pipeline includes triple agonists, oral alternatives, combination therapies, and compounds targeting liver fat alongside body weight.

The pharmaceutical industry has clearly decided that the obesity market is worth the investment. Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Amgen, Pfizer, and several Chinese pharmaceutical companies are all racing to bring the next generation to market.

Here is every significant compound in the pipeline, organized by how close each is to your medicine cabinet.

Retatrutide -- the triple agonist (Eli Lilly)

Mechanism: GLP-1 + GIP + Glucagon receptor triple agonist Status: Phase 3 (TRIUMPH program) Estimated approval: Late 2027 or 2028

Retatrutide produced the highest weight loss ever recorded in a controlled obesity trial. The Phase 2 data, published in the New England Journal of Medicine, showed 24.2% average body weight loss at 48 weeks at the 12mg dose -- and the weight loss curves had not plateaued (PMID: 37351564).

What sets retatrutide apart is the glucagon receptor. While semaglutide targets one receptor (GLP-1) and tirzepatide targets two (GLP-1 + GIP), retatrutide targets three. The glucagon component does something the others do not do as effectively: it drives energy expenditure upward and targets liver fat directly.

In the Phase 2 trial, the liver fat findings were striking. A substantial majority of participants on the highest dose achieved normalization of liver fat content. For patients with metabolic dysfunction-associated steatotic liver disease (MASLD), this could be as significant as the weight loss itself.

Key Phase 3 questions:

• Will the 24% weight loss hold up in larger, longer trials?
• What is the full safety profile at scale?
• Will the GI side effect profile remain manageable with dose titration?
• How will Eli Lilly price it relative to Zepbound (tirzepatide)?

The TRIUMPH Phase 3 program includes multiple trials across different populations. Results are expected to begin reading out in late 2026 or early 2027.

Orforglipron -- the pill that could change everything (Eli Lilly)

Mechanism: Oral non-peptide GLP-1 receptor agonist Status: Phase 3 (ATTAIN program) Estimated approval: 2026-2027

Orforglipron is not technically a peptide. It is a small molecule that activates the GLP-1 receptor. This distinction matters enormously because small molecules do not have the bioavailability problems that peptides do when taken orally.

Recall that oral semaglutide (Rybelsus) has roughly 1% bioavailability -- 99% of the pill is destroyed before it can be absorbed. Orforglipron sidesteps this entirely. As a non-peptide, it is absorbed through the GI tract with far greater efficiency. No fasting requirement. No tiny-sip-of-water protocol.

Phase 3 data showed approximately 14.7% weight loss at 36 weeks (PMID: 38587993). That is comparable to injectable semaglutide at a similar timepoint -- but in a daily pill.

Why this matters:

• Needle aversion remains the single biggest barrier to GLP-1 adoption
• An effective oral GLP-1 expands the addressable patient population dramatically
• Manufacturing oral pills is cheaper than injectable pens, potentially lowering cost
• Daily dosing (vs weekly injection) gives patients more granular dose control

What to watch:

• Longer-term weight loss data (will it match or exceed injectable semaglutide at 68+ weeks?)
• Liver enzyme signals observed in some trials need careful monitoring
• Pricing strategy -- will Eli Lilly price it below injectable options?

If orforglipron delivers on its promise, it could become the most prescribed weight loss medication in history simply by removing the injection barrier.

Survodutide -- the liver fat specialist (Boehringer Ingelheim)

Mechanism: Dual GLP-1 + Glucagon receptor agonist Status: Phase 3 (for MASH and obesity) Estimated approval: 2027

Survodutide targets two receptors, but a different two than tirzepatide. Instead of GLP-1 + GIP, survodutide combines GLP-1 + glucagon. This makes it mechanistically similar to the glucagon component of retatrutide.

Phase 2 data showed approximately 18.7% weight loss at 46 weeks. Competitive with tirzepatide at similar timepoints.

But the real story is the liver. Survodutide is being developed in parallel for MASH (metabolic dysfunction-associated steatohepatitis), a serious liver condition affecting an estimated 6-8 million Americans. Glucagon receptor activation drives hepatic fat oxidation -- literally burning fat out of the liver.

The Phase 2b MASH trial showed that survodutide produced MASH resolution (disease reversal) in a significant portion of participants, with concurrent improvement in liver fibrosis. For context, MASH currently has very few effective treatments, and the condition progresses to cirrhosis and liver failure if untreated.

Why this is significant beyond weight loss: A compound that addresses both obesity and MASH simultaneously hits two massive markets with one drug. Boehringer Ingelheim is positioning survodutide as a metabolic disease treatment, not just a weight loss drug.

CagriSema -- the combination play (Novo Nordisk)

Mechanism: Semaglutide 2.4mg + Cagrilintide (amylin analog) in a single weekly injection Status: Phase 3 (REDEFINE program) Estimated approval: 2026-2027

Novo Nordisk's strategy for staying competitive against Eli Lilly's pipeline is CagriSema -- a fixed-dose combination of their existing semaglutide with cagrilintide, a long-acting amylin analog.

Amylin is a hormone co-secreted with insulin that promotes satiety, slows gastric emptying, and suppresses glucagon. By layering amylin-mediated appetite suppression on top of GLP-1 signaling, CagriSema aims to produce greater weight loss than semaglutide alone.

Phase 3 data showed approximately 22.7% weight loss, putting it in competitive range with tirzepatide and approaching retatrutide territory. This is Novo Nordisk's answer to being outperformed by tirzepatide in the SURMOUNT-5 head-to-head trial (PMID: 37840095).

Key advantage: CagriSema could reach market before retatrutide, giving Novo Nordisk a higher-efficacy option while they await their own next-generation compounds.

Mazdutide -- the Chinese market contender (Innovent Biologics)

Mechanism: Dual GLP-1 + Glucagon receptor agonist Status: Phase 3 (primarily in China) Estimated timeline: Approved in China, US timeline uncertain

Mazdutide is developed by Innovent Biologics in partnership with Eli Lilly (who licensed the molecule for the Chinese market). It is a dual GLP-1/glucagon agonist, mechanistically similar to survodutide.

Phase 3 data in Chinese populations showed competitive weight loss results. Mazdutide has been advancing through China's regulatory process and could become one of the first multi-receptor agonists approved in that market.

Relevance to Western markets: Limited in the near term. But China's obesity epidemic is massive and growing. Mazdutide's success or failure in that market will influence global development strategies for the entire class.

Pemvidutide -- the smaller dual agonist (Altimmune)

Mechanism: Dual GLP-1 + Glucagon receptor agonist Status: Phase 2 (advancing toward Phase 3) Estimated approval: 2028+

Pemvidutide is another GLP-1/glucagon dual agonist, developed by Altimmune. Phase 2 data showed meaningful weight loss and liver fat reduction, though the numbers are more modest than survodutide or retatrutide at comparable timepoints.

The smaller biotech footprint means pemvidutide gets less attention, but it contributes to the broader trend: the industry is converging on multi-receptor approaches as the future of metabolic disease treatment.

What this pipeline means for you

The direction is clear. The weight loss peptide market is moving from:

Single-target (one receptor) to multi-target (two or three receptors). Every major pipeline compound targets multiple metabolic pathways simultaneously. The era of single-receptor GLP-1s as the ceiling of efficacy is ending.

Injectable-only to oral options. Orforglipron could open GLP-1 therapy to millions of people who currently refuse treatment because of needles.

Weight-loss-only to metabolic disease platforms. Compounds like survodutide and retatrutide are being developed for MASH, cardiovascular disease, and sleep apnea in addition to obesity. The framing is shifting from "weight loss drugs" to "metabolic disease treatments."

Scarcity to competition. By 2028, patients and prescribers will likely have 5-7 options in this class, driving competition on price, efficacy, tolerability, and convenience.

What to do with this information now

If you are currently on semaglutide or tirzepatide and getting good results, there is no reason to wait for a pipeline compound. The medications available today are already producing life-changing outcomes for millions of people.

If you are waiting to start treatment because you want the "best" option -- the best option available today is better than a theoretical option available in 2028. Discuss current FDA-approved treatments with your healthcare provider.

For ongoing comparisons between the current leaders, see our semaglutide vs tirzepatide breakdown. For a detailed look at the compound with the highest clinical weight loss data to date, read our retatrutide Phase 2 results analysis.

We will continue to update this page as Phase 3 data reads out and new compounds enter the pipeline. The weight loss landscape in 2026 is moving fast.

Sources

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526. PMID: 37351564
2. Wharton S, et al. Tirzepatide vs Semaglutide for Weight Loss (SURMOUNT-5). PMID: 37840095
3. Frias JP, et al. Orforglipron in Adults with Obesity. N Engl J Med. 2024. PMID: 38587993
4. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
5. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024

---

This article is for educational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. See our full medical disclaimer.